Opus Genetics, Inc. (IRD) Revenue History
Annual and quarterly revenue from 2019 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
IRD Revenue Growth
IRD Revenue Analysis (2019–2024)
As of May 8, 2026, Opus Genetics, Inc. (IRD) generated trailing twelve-month (TTM) revenue of $14.6 million, reflecting significant decline in growth of -20.4% year-over-year. The most recent quarter (Q3 2025) recorded $3.1 million in revenue, up 6.8% sequentially.
Looking at the longer-term picture, IRD's historical revenue data shows a 3-year CAGR of +165.2%. The company achieved its highest annual revenue of $39.9 million in 2022.
When compared to Healthcare sector peers including JANX (+68.9% YoY), KRYS (+25.1% YoY), and BEAM (+108.0% YoY), IRD has underperformed the peer group in terms of revenue growth. Compare IRD vs JANX →
IRD Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| IRDCurrent | $15M | -20.4% | - | -564.7% | |
 JANX | $10M | +68.9% | - | -1576.7% | |
 KRYS | $389M | +25.1% | - | 41.5% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% |
IRD Historical Revenue Data (2019–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $11.0M | -42.3% | $11.0M | 100.0% | $-62,074,000 | -564.7% |
| 2023 | $19.0M | -52.2% | $19.0M | 100.0% | $-10,563,000 | -55.5% |
| 2022 | $39.9M | +6665.7% | $39.9M | 100.0% | $18.2M | 45.7% |
| 2021 | $589K | - | $589K | 100.0% | $-22,705,000 | -3854.8% |
| 2020 | $0 | - | $0 | - | $-19,968,000 | - |
| 2019 | $0 | - | $0 | - | $-4,193,000 | - |
See IRD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IRD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IRD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIRD — Frequently Asked Questions
Quick answers to the most common questions about buying IRD stock.
Is IRD's revenue growth accelerating or slowing?
IRD revenue declined -20.4% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $15M. This reverses the prior growth trend.
What is IRD's long-term revenue growth rate?
Opus Genetics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -20.4% is below this long-term average.
How is IRD's revenue distributed by segment?
IRD reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2024 are available for download. Segment mix reveals concentration and diversification trends.